The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Landmark analysis of overall survival (OS) by objective response in patients (pts) with previously treated, advanced HER2-positive biliary tract cancer (BTC): Post hoc analysis of the HERIZON-BTC-01 trial.
 
James Harding
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Cogent Medicine; Elevar Therapeutics; Exelixis; Jazz Pharmaceuticals; Merck; RayzeBio; SERVIER
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst); Jazz Pharmaceuticals (Inst); Kinnate Biopharma (Inst); Lilly (Inst); Tvardi Therapeutics (Inst); yivvia (Inst); Zymeworks (Inst)
 
Jia Fan
No Relationships to Disclose
 
Do-Youn Oh
Consulting or Advisory Role - Abbvie; Alligtor Bioscience AB; Arcus Biosciences; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Eutilex; Genentech/Roche; Halozyme; Hana Pharm; Hanmi; Idience; IQVIA; J-Pharma; LG Chem; Merck Serono; Mirati Therapeutics; Moderna Therapeutics; MSD Oncology; Novartis; Revolution Medicines; Taiho Pharmaceutical; Tallac Therapeutics; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Hanmi; Lilly; MSD; Novartis; SERVIER
 
Hye Jin Choi
Consulting or Advisory Role - AstraZeneca; MSD Oncology
 
Jin Won Kim
Consulting or Advisory Role - AstraZeneca; BeiGene Beijing; BeiGene Beijing; BeyondBIO; Bristol-Myers Squibb/Celgene; Eisai; GC Cell; MSD; Ono Pharmaceutical; Roche; Sanofi; Servier; TCUBEit
Research Funding - Boryung Pharmaceuticals; Samyang
 
Heung-Moon Chang
Research Funding - Astellas Pharma (Inst); Taiho Oncology (Inst); Zymeworks (Inst)
 
Lequn Bao
No Relationships to Disclose
 
Hui-Chuan Sun
Employment - Zhongshan Hospital, Fudan University
Honoraria - AstraZeneca; Bayer; BeiGene; Eisai; Hengrui Pharmaceutical; Innovent Biologics; MSD; Roche; TopAlliance BioSciences Inc; Zelgen
Research Funding - Innovent Biologics (Inst); MSD (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Radiomic features to predict tumor response to systemic therapy in liver cancer patients (Inst)
 
Teresa Macarulla
Consulting or Advisory Role - Ability Pharma; Advance Medical; Alligator Bioscience; Amgen; Aptitude Health; Arcus Biosciences; Astellas Pharma; AstraZeneca; Basilea; Baxter; BioLineRX; Boehringer Ingelheim; Celgene; Eisai; Ellipses Pharma; Esteve; Incyte; Ipsen; Janssen; Janssen; Lilly; Medscape; MFAR, Marketing Farmacéutico & Investigación Clínica; MSD; Novocure; Novocure; Paraxel; PEGASCY; Prime Oncology; QED Therapeutics; Revolution Medicines; Roche; Sanofi/Aventis; SERVIER; Taiho / Keylates; Zymeworks
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Agios (Inst); Amc Medical Research (Inst); Amgen (Inst); Armo Biosciences (Inst); ASLAN Pharmaceuticals (Inst); ASTRAZENECA (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Beigene (Inst); BiolineRx (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (BMS) (Inst); Cantargia AB (Inst); Celgene (Inst); Eisai (Inst); ERYTECH Pharma (Inst); Fibrogen (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Incyte (Inst); Ipsen (Inst); Keralty Group (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Millennium (Inst); Nelum Corp. (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); VCN Biosciences (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER
 
Feng Xie
No Relationships to Disclose
 
Jean-Philippe Metges
Honoraria - Amgen; Beigene; BeiGene; Gilead Sciences; MSD Oncology; Pierre Fabre; Pierre Fabre
Consulting or Advisory Role - Bayer; BeiGene; BeiGene; Daiichi Sankyo Europe GmbH; MSD Oncology
Travel, Accommodations, Expenses - BeiGene; MSD Oncology
 
Jieer Ying
No Relationships to Disclose
 
John Bridgewater
Honoraria - Incyte; SERVIER
Consulting or Advisory Role - AstraZeneca; Basilea; Bayer; Incyte; Merck Serono; Merck Serono; Roche; SERVIER; Taiho Oncology
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Jazz Pharmaceuticals; SERVIER
Research Funding - Amgen; Incyte (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb/Medarex; Merck Serono; MSD Oncology; SERVIER
 
Harpreet Wasan
Honoraria - Array BioPharma; Celgene; ERYTECH Pharma; Incyte; Merck KGaA; Roche/Genentech; Servier; Sirtex Medical; Zymeworks
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; ERYTECH Pharma; EXACT Therapeutics; Incyte; Jazz Pharmaceuticals/zymeworks; Nordicpharma; Pfizer; Pierre Fabre; Roche Pharma AG; Shire; Sirtex medical; Taiho Oncology; Takeda
Speakers' Bureau - Celgene; Incyte; Merck KGaA; SERVIER; Sirtex Medical
Research Funding - Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Sirtex Medical (Inst)
Expert Testimony - Bayer; Oncosil
 
Michel Ducreux
Employment - Sandoz (I)
Stock and Other Ownership Interests - ABCELY
Honoraria - Amgen; Bayer; Pierre Fabre; Roche/Genentech; TERUMO
Consulting or Advisory Role - Abbvie (Inst); Abcely; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS GmbH & Co. KG; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Ipsen; Janssen; Jazz Pharmaceuticals; Lilly; Merck Serono; MSD; Novartis; Pierre Fabre; Rafael Pharmaceuticals; Revolution Medicines; Roche; Scandion Oncology; SERVIER; Servier; Sotio; Zymeworks
Speakers' Bureau - Amgen; AstraZeneca; Bayer; GlaxoSmithKline; HalioDx; Lilly; Merck KGaA; MSD; Pierre Fabre; Roche; SERVIER
Research Funding - Keocyt (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Merck Serono; Pierre Fabre; Roche; SERVIER
(OPTIONAL) Uncompensated Relationships - Astellas Pharma; Revolution Medicines
 
Zinan Bao
Employment - BeOne Medicines
Stock and Other Ownership Interests - BeOne Medicines
 
Phillip Garfin
Employment - Jazz Pharmaceuticals
Stock and Other Ownership Interests - Jazz Pharmaceuticals
 
Douglas Fuller
Employment - Jazz Pharmaceuticals
Stock and Other Ownership Interests - Jazz Pharmaceuticals
 
Parveen Jayia
Employment - AstraZeneca; Jazz Pharmaceuticals
Stock and Other Ownership Interests - AstraZeneca; Jazz Pharmaceuticals
 
Shubham Pant
Stock and Other Ownership Interests - Teleprian
Consulting or Advisory Role - Alligator Bioscience; Arcus Biosciences; AskGene Pharma; AstraZeneca; Boehringer Ingelheim; BPGbio; Ipsen; Janssen; Jazz Pharmaceuticals; Merck; Nihon Medi-Physics; Novartis; Pfizer; Revolution Medicines; US WorldMeds
Research Funding - 4D Pharma (Inst); Amal Therapeutics (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); bionte (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Immuneering (Inst); ImmunoMET (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Purple Biotech (Inst); Rgenix (Inst); Xencor (Inst); Zymeworks (Inst)